Skip to main content

Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a major Chinese research-driven pharmaceutical conglomerate that develops, manufactures, and markets chemical medicines and biologics. The company conducts business through primary medical categories including oncology, liver diseases, respiratory indications, surgery, and orthopedic treatments. Its principal revenue drivers consist of high-volume sales of prescription drugs, novel biopharmaceuticals, generic medicines, and active pharmaceutical ingredients to hospitals and healthcare providers. Sino Biopharmaceutical holds a leading market position as one of China's largest pharmaceutical companies, maintaining extensive commercialization networks and advanced research facilities across Mainland China. The enterprise focuses heavily on increasing R&D investments in innovative therapies, advancing clinical trials for targeted cancer drugs, acquiring international biopharmaceutical assets, and digitizing healthcare distribution. Sino Biopharmaceutical Limited is headquartered in Hong Kong, and its common shares are publicly listed and traded on the Hong Kong Stock Exchange.

21 of the funds FundTelligence covers report a position in Sino Biopharmaceutical.

Legal name
Sino Biopharmaceutical Ltd.
Sector
Health Care
Country
Hong Kong SAR China
Funds holding it
21

Funds holding Sino Biopharmaceutical

Showing the 8 largest of 21 funds holding it.

Loading...